{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T07:06:43Z","timestamp":1780988803542,"version":"3.54.1"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"National Institutes of Health Cancer Center Support","award":["P30CA006973"],"award-info":[{"award-number":["P30CA006973"]}]},{"name":"Department of Defense Prostate Cancer Research Program","award":["W81XWH-22-2-0024"],"award-info":[{"award-number":["W81XWH-22-2-0024"]}]},{"DOI":"10.13039\/100016737","name":"Patrick C Walsh Prostate Cancer Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016737","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Identification and characterization of prostate tumor markers differentially expressed in European American (EA) men vs African American (AA) men has been one of the focus areas positioned to understand and address prostate cancer disparity in the US. Whereas some genes are differentially expressed, validation studies are limited, and the impact of these expression differences on recurrence risk remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study focused on phospholipase A2 group 7 (PLA2G7) in prostate cancer surgical specimens from EA and AA patients. A nested case-control study was conducted to evaluate the prognostic value of the PLA2G7 protein while controlling for age, stage, and Gleason, followed by re-analysis of a published dataset of 556 EA and 596 AA prostate cancer patients. Expression signatures correlated with PLA2G7 were investigated in both patient populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>PLA2G7 was more frequently overexpressed in EA tumors than AA tumors, and higher tumor-specific PLA2G7 expression was associated with divergent outcomes: lower biochemical recurrence risk in EA men but elevated risk in AA men. Expression in noncancer tissues showed no prognostic value. Whereas androgen response signatures were consistently enriched in high-PLA2G7 tumors across both groups, immune and inflammatory response gene sets showed opposite enrichment trends between AA and EA men.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study represents the first identification and validation of a tumor-specific marker that is both differentially expressed between prostate cancers in AA and EA men and demonstrates opposite prognostic effects based on self-reported race\/ethnicity. The findings emphasize the importance of evaluating prostate tumor markers across diverse geographic ancestries.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jnci\/djag036","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T12:53:34Z","timestamp":1770382414000},"page":"1097-1107","source":"Crossref","is-referenced-by-count":0,"title":["Divergent effects of PLA2G7 on prostate cancer biochemical recurrence in European American and African American men"],"prefix":"10.1093","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3658-1858","authenticated-orcid":false,"given":"Channing J","family":"Paller","sequence":"first","affiliation":[{"name":"Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine , Baltimore, MD,","place":["USA"]},{"name":"Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine , Baltimore, MD,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0441-6973","authenticated-orcid":false,"given":"Shuanzeng","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Pathology, Fox Chase Cancer Center , Philadelphia, PA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0973-0639","authenticated-orcid":false,"given":"Megan","family":"Schumacher","sequence":"additional","affiliation":[{"name":"Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine , Baltimore, MD,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9570-2081","authenticated-orcid":false,"given":"Daniel","family":"Rabizadeh","sequence":"additional","affiliation":[{"name":"Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine , Baltimore, MD,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ching","family":"Hsu","sequence":"additional","affiliation":[{"name":"Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine , Baltimore, MD,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7565-8796","authenticated-orcid":false,"given":"Changxue","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine , Baltimore, MD,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, the University of Texas Health San Antonio , San Antonio, TX,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuezhou","family":"Jing","sequence":"additional","affiliation":[{"name":"Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine , Baltimore, MD,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3529-9295","authenticated-orcid":false,"given":"Bruce J","family":"Trock","sequence":"additional","affiliation":[{"name":"Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine , Baltimore, MD,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1947-6311","authenticated-orcid":false,"given":"Mayuko","family":"Kanayama","sequence":"additional","affiliation":[{"name":"Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine , Baltimore, MD,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7651-9309","authenticated-orcid":false,"given":"Stefan","family":"Ambs","sequence":"additional","affiliation":[{"name":"Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, NIH , Bethesda, MD,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3607-2981","authenticated-orcid":false,"given":"Diana M","family":"Stafforini","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute, University of Utah , Salt Lake City, UT,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6599-6775","authenticated-orcid":false,"given":"William B","family":"Isaacs","sequence":"additional","affiliation":[{"name":"Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine , Baltimore, MD,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3915-9134","authenticated-orcid":false,"given":"George J","family":"Netto","sequence":"additional","affiliation":[{"name":"Department of Pathology and Lab Med, University of Pennsylvania , Philadelphia, PA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0494-9067","authenticated-orcid":false,"given":"Tamara L","family":"Lotan","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine , Baltimore, MD,","place":["USA"]},{"name":"Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine , Baltimore, MD,","place":["USA"]},{"name":"Department of Pathology, Johns Hopkins University School of Medicine , Baltimore, MD,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4847-5307","authenticated-orcid":false,"given":"Angelo M","family":"De Marzo","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine , Baltimore, MD,","place":["USA"]},{"name":"Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine , Baltimore, MD,","place":["USA"]},{"name":"Department of Pathology, Johns Hopkins University School of Medicine , Baltimore, MD,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3676-8954","authenticated-orcid":false,"given":"Elizabeth A","family":"Platz","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine , Baltimore, MD,","place":["USA"]},{"name":"Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine , Baltimore, MD,","place":["USA"]},{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health , Baltimore, MD,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1414-473X","authenticated-orcid":false,"given":"Jun","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine , Baltimore, MD,","place":["USA"]},{"name":"Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine , Baltimore, MD,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"2026060902511438000_djag036-B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2026060902511438000_djag036-B2","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1001\/jamaoncol.2019.0812","article-title":"Racial inequality in prostate cancer outcomes-socioeconomics, not biology","volume":"5","author":"Paller","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026060902511438000_djag036-B3","doi-asserted-by":"publisher","first-page":"S112","DOI":"10.5213\/inj.1632722.361","article-title":"Racial differences in the diagnosis and treatment of prostate cancer","volume":"20","author":"Pietro","year":"2016","journal-title":"Int Neurourol J"},{"key":"2026060902511438000_djag036-B4","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.urology.2014.05.009","article-title":"Trends in disparate treatment of African American men with localized prostate cancer across National Comprehensive Cancer Network risk groups","volume":"84","author":"Mahal","year":"2014","journal-title":"Urology"},{"key":"2026060902511438000_djag036-B5","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1001\/jamaoncol.2019.0826","article-title":"Association of black race with prostate cancer-specific and other-cause mortality","volume":"5","author":"Dess","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026060902511438000_djag036-B6","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/cncr.33224","article-title":"Outcomes of Black men with prostate cancer treated with radiation therapy in the Veterans Health Administration","volume":"127","author":"McKay","year":"2021","journal-title":"Cancer"},{"key":"2026060902511438000_djag036-B7","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.urology.2007.11.024","article-title":"Impact of socioeconomic factors on prostate cancer outcomes in black patients treated with surgery","volume":"72","author":"Dash","year":"2008","journal-title":"Urology"},{"key":"2026060902511438000_djag036-B8","doi-asserted-by":"publisher","first-page":"982","DOI":"10.3892\/mco.2014.378","article-title":"Predominance of ERG-negative high-grade prostate cancers in African American men","volume":"2","author":"Farrell","year":"2014","journal-title":"Mol Clin Oncol"},{"key":"2026060902511438000_djag036-B9","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1200\/JCO.2014.59.8912","article-title":"Novel biomarker signature that may predict aggressive disease in African American men with prostate cancer","volume":"33","author":"Yamoah","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026060902511438000_djag036-B10","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1158\/2159-8290.CD-16-0960","article-title":"Exome sequencing of African-American prostate cancer reveals loss-of-function ERF mutations","volume":"7","author":"Huang","year":"2017","journal-title":"Cancer Discov"},{"key":"2026060902511438000_djag036-B11","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.eururo.2016.07.026","article-title":"Prevalence and prognostic significance of PTEN loss in African-American and European-American men undergoing radical prostatectomy","volume":"71","author":"Tosoian","year":"2017","journal-title":"Eur Urol"},{"key":"2026060902511438000_djag036-B12","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1158\/1078-0432.CCR-19-1669","article-title":"CDKN1B deletions are associated with metastasis in African American men with clinically localized, surgically treated prostate cancer","volume":"26","author":"Faisal","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026060902511438000_djag036-B13","first-page":"129","article-title":"The prostate\u2014overview: recent insights and speculations","author":"Gardner","year":"1992","journal-title":"Monogr Pathol"},{"key":"2026060902511438000_djag036-B14","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(03)12779-1","article-title":"Pathological and molecular aspects of prostate cancer","volume":"361","author":"DeMarzo","year":"2003","journal-title":"Lancet"},{"key":"2026060902511438000_djag036-B15","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1056\/NEJMra021562","article-title":"Prostate cancer","volume":"349","author":"Nelson","year":"2003","journal-title":"N Engl J Med"},{"key":"2026060902511438000_djag036-B16","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/nrc2090","article-title":"Inflammation in prostate carcinogenesis.Review","volume":"7","author":"De Marzo","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"2026060902511438000_djag036-B17","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/jnci\/90.10.756","article-title":"Clinical characteristics and biopsy specimen features in African-American and white men without prostate cancer","volume":"90","author":"Eastham","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"2026060902511438000_djag036-B18","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1158\/0008-5472.CAN-07-2608","article-title":"Tumor immunobiological differences in prostate cancer between African-American and European-American men","volume":"68","author":"Wallace","year":"2008","journal-title":"Cancer Res"},{"key":"2026060902511438000_djag036-B19","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/374549a0","article-title":"Anti-inflammatory properties of a platelet-activating factor acetylhydrolase","volume":"374","author":"Tjoelker","year":"1995","journal-title":"Nature"},{"key":"2026060902511438000_djag036-B20","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/0006-291X(83)91778-3","article-title":"Inactivation of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine by a plasma acetylhydrolase: higher activities in hypertensive rats","volume":"113","author":"Blank","year":"1983","journal-title":"Biochem Biophys Res Commun"},{"key":"2026060902511438000_djag036-B21","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1146\/annurev.bi.55.070186.002411","article-title":"Platelet activating factor: a biologically active phosphoglyceride","volume":"55","author":"Hanahan","year":"1986","journal-title":"Annu Rev Biochem"},{"key":"2026060902511438000_djag036-B22","first-page":"4683","article-title":"Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling","volume":"61","author":"Luo","year":"2001","journal-title":"Cancer Res"},{"key":"2026060902511438000_djag036-B23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1158\/0008-5472.CAN-08-2764","article-title":"Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer","volume":"69","author":"Hu","year":"2009","journal-title":"Cancer Res"},{"key":"2026060902511438000_djag036-B24","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1002\/pros.20806","article-title":"GOLPH2 and MYO6: putative prostate cancer markers localized to the Golgi apparatus","volume":"68","author":"Wei","year":"2008","journal-title":"Prostate"},{"key":"2026060902511438000_djag036-B25","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1097\/PAS.0b013e31821e8761","article-title":"Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas","volume":"35","author":"Chaux","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"2026060902511438000_djag036-B26","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1038\/modpathol.2012.104","article-title":"Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer","volume":"25","author":"Chaux","year":"2012","journal-title":"Mod Pathol"},{"key":"2026060902511438000_djag036-B27","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1158\/1055-9965.EPI-08-0839","article-title":"A simulation study of control sampling methods for nested case-control studies of genetic and molecular biomarkers and prostate cancer progression","volume":"18","author":"Wang","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2026060902511438000_djag036-B28","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1385\/1-59259-780-7:089","article-title":"Practical methods for tissue microarray construction","volume":"103","author":"Fedor","year":"2005","journal-title":"Methods Mol Med"},{"key":"2026060902511438000_djag036-B29","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1111\/j.1420-9101.2005.00917.x","article-title":"Combining probability from independent tests: the weighted Z-method is superior to Fisher\u2019s approach","volume":"18","author":"Whitlock","year":"2005","journal-title":"J Evol Biol"},{"key":"2026060902511438000_djag036-B30","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/s42003-021-02140-y","article-title":"Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences","volume":"4","author":"Rayford","year":"2021","journal-title":"Commun Biol"},{"key":"2026060902511438000_djag036-B31","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.2353\/ajpath.2006.060316","article-title":"A novel role of myosin VI in human prostate cancer","volume":"169","author":"Dunn","year":"2006","journal-title":"Am J Pathol"},{"key":"2026060902511438000_djag036-B32","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.18632\/oncotarget.397","article-title":"Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins","volume":"2","author":"Vainio","year":"2011","journal-title":"Oncotarget"},{"key":"2026060902511438000_djag036-B33","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.ajpath.2010.10.002","article-title":"Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer","volume":"178","author":"Vainio","year":"2011","journal-title":"Am J Pathol"},{"key":"2026060902511438000_djag036-B34","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1006\/bbrc.1999.1066(99)91066-5","article-title":"Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma","volume":"261","author":"Asano","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"2026060902511438000_djag036-B35","doi-asserted-by":"publisher","first-page":"10242","DOI":"10.1158\/0008-5472.CAN-06-1986","article-title":"TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming","volume":"66","author":"Iljin","year":"2006","journal-title":"Cancer Res"},{"key":"2026060902511438000_djag036-B36","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1158\/1055-9965.EPI-12-1238","article-title":"Genes associated with prostate cancer are differentially expressed in African American and European American men","volume":"22","author":"Powell","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2026060902511438000_djag036-B37","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1203\/PDR.0b013e3181eb2efe","article-title":"Dual roles of endogenous platelet-activating factor acetylhydrolase in a murine model of necrotizing enterocolitis","volume":"68","author":"Lu","year":"2010","journal-title":"Pediatr Res"},{"key":"2026060902511438000_djag036-B38","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1042\/bj3380479","article-title":"Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor","volume":"338(Pt 2)","author":"MacPhee","year":"1999","journal-title":"Biochem J"},{"key":"2026060902511438000_djag036-B39","doi-asserted-by":"crossref","first-page":"20963","DOI":"10.1074\/jbc.272.34.20963","article-title":"Low density lipoprotein oxidation and its pathobiological significance","volume":"272","author":"Steinberg","year":"1997","journal-title":"J Biol Chem"},{"key":"2026060902511438000_djag036-B40","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1161\/01.ATV.19.12.2909","article-title":"Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions","volume":"19","author":"Hakkinen","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol. Dec"},{"key":"2026060902511438000_djag036-B41","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/nm.1870","article-title":"Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development","volume":"14","author":"Wilensky","year":"2008","journal-title":"Nat Med"},{"key":"2026060902511438000_djag036-B42","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1097\/HCO.0b013e32832bcb22","article-title":"Lipoprotein-associated phospholipase A2 as a biomarker of coronary heart disease and a therapeutic target","volume":"24","author":"Packard","year":"2009","journal-title":"Curr Opin Cardiol"},{"key":"2026060902511438000_djag036-B43","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1056\/NEJMoa1315878","article-title":"Darapladib for preventing ischemic events in stable coronary heart disease","volume":"370","author":"Investigators","year":"2014","journal-title":"N Engl J Med"},{"key":"2026060902511438000_djag036-B44","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1194\/jlr.E052886","article-title":"Unraveling the PAF-AH\/Lp-PLA2 controversy","volume":"55","author":"Stafforini","year":"2014","journal-title":"J Lipid Res"},{"key":"2026060902511438000_djag036-B45","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1194\/jlr.R045492","article-title":"To hydrolyze or not to hydrolyze: the dilemma of platelet-activating factor acetylhydrolase","volume":"55","author":"Marathe","year":"2014","journal-title":"J Lipid Res"},{"key":"2026060902511438000_djag036-B46","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1038\/s41379-018-0083-x","article-title":"Association of tumor-infiltrating T-cell density with molecular subtype, racial ancestry and clinical outcomes in prostate cancer","volume":"31","author":"Kaur","year":"2018","journal-title":"Mod Pathol"},{"key":"2026060902511438000_djag036-B47","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/s41467-021-21245-w","article-title":"Plasma cells are enriched in localized prostate cancer in Black men and are associated with improved outcomes","volume":"12","author":"Weiner","year":"2021","journal-title":"Nat Commun"},{"key":"2026060902511438000_djag036-B48","author":"Hamilton","year":"2020"},{"key":"2026060902511438000_djag036-B49","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1158\/2767-9764.CRC-24-0112","article-title":"Race-related differences in sipuleucel-T response among men with metastatic castrate-resistant prostate cancer","volume":"4","author":"Heath","year":"2024","journal-title":"Cancer Res Commun"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djag036\/67296946\/djag036.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/118\/6\/1097\/67296946\/djag036.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/118\/6\/1097\/67296946\/djag036.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T06:51:26Z","timestamp":1780987886000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/118\/6\/1097\/8513793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":49,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,3,13]]},"published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djag036","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,3,13]]}}}